Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 706321 in healthy Japanese and Chinese male subjects
NCT05183360Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2022
- Primary completion
- Aug 2022
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bi 706321 (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of Participants With Drug-related Adverse Events at 35 days. Started Feb 2022; status: terminated.
02
Drugs
bi 706321
Beyond the preview
Go deeper on NCT05183360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05183360.